Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-Blind Trial of the Clinical Activity and Safety of Å6 in Patients With Asymptomatic CA125 Progression of Epithelial Ovarian Cancer After First-Line Chemotherapy

NCT00083928 is registered in ClinicalTrials.gov with Ångstrom Pharmaceuticals as lead sponsor.

NCT NCT00083928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00083928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-Blind Trial of the Clinical Activity and Safety of Å6 in Patients With Asymptomatic CA125 Progression of Epithelial Ovarian Cancer After First-Line Chemotherapy
Lead sponsor
Ångstrom Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
December 31, 2006
Enrollment
60 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, primary peritoneal carcinoma